全文获取类型
收费全文 | 3350篇 |
免费 | 230篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 57篇 |
儿科学 | 128篇 |
妇产科学 | 92篇 |
基础医学 | 474篇 |
口腔科学 | 124篇 |
临床医学 | 317篇 |
内科学 | 629篇 |
皮肤病学 | 26篇 |
神经病学 | 274篇 |
特种医学 | 127篇 |
外科学 | 337篇 |
综合类 | 23篇 |
一般理论 | 4篇 |
预防医学 | 294篇 |
眼科学 | 64篇 |
药学 | 351篇 |
中国医学 | 1篇 |
肿瘤学 | 263篇 |
出版年
2024年 | 5篇 |
2023年 | 16篇 |
2022年 | 32篇 |
2021年 | 43篇 |
2020年 | 53篇 |
2019年 | 72篇 |
2018年 | 87篇 |
2017年 | 68篇 |
2016年 | 98篇 |
2015年 | 99篇 |
2014年 | 112篇 |
2013年 | 180篇 |
2012年 | 233篇 |
2011年 | 219篇 |
2010年 | 135篇 |
2009年 | 131篇 |
2008年 | 233篇 |
2007年 | 241篇 |
2006年 | 252篇 |
2005年 | 195篇 |
2004年 | 192篇 |
2003年 | 158篇 |
2002年 | 183篇 |
2001年 | 27篇 |
2000年 | 27篇 |
1999年 | 29篇 |
1998年 | 44篇 |
1997年 | 42篇 |
1996年 | 53篇 |
1995年 | 27篇 |
1994年 | 25篇 |
1993年 | 24篇 |
1992年 | 13篇 |
1991年 | 18篇 |
1990年 | 21篇 |
1989年 | 20篇 |
1988年 | 17篇 |
1987年 | 13篇 |
1986年 | 11篇 |
1985年 | 16篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 8篇 |
1979年 | 15篇 |
1978年 | 14篇 |
1977年 | 10篇 |
1975年 | 9篇 |
1972年 | 5篇 |
排序方式: 共有3585条查询结果,搜索用时 15 毫秒
131.
132.
Walsh SH Thorsélius M Johnson A Söderberg O Jerkeman M Björck E Eriksson I Thunberg U Landgren O Ehinger M Löfvenberg E Wallman K Enblad G Sander B Porwit-MacDonald A Dictor M Olofsson T Sundström C Roos G Rosenquist R 《Blood》2003,101(10):4047-4054
Mantle cell lymphoma (MCL) is believed to originate from a naive B cell. However, we recently demonstrated that a subset of MCL displayed mutated V(H) genes. We also reported restricted use of certain V(H) genes. To assess the prognostic impact of these new findings, we performed V(H) gene analysis of 110 patients, revealing that 18 (16%) patients had mutated and 92 (84%) patients had unmutated V(H) genes. Because the mutation rate was low in the mutated group (2.2%-6.7%), further investigation of the germline V(H) gene in T cells from 5 patients with mutated V(H) genes was carried out; results showed that the unrearranged V(H) gene was identical to the published sequence. These data confirm that the base pair substitutions within the rearranged V(H) genes represent hypermutations, and indicate germinal center exposure. However, V(H) gene mutation status did not correlate with prognosis because there was no difference in clinical outcome between the unmutated and mutated groups. The most frequently used V(H) genes were V(H)3-21 (21 patients) and V(H)4-34 (19 patients). A novel finding was that V(H)3-21(+) MCL almost exclusively expressed lambda light chains and displayed highly restricted use of the V(lambda)3-19 gene. V(H)3-21(+) patients had longer median survival than the remaining patients (53 vs 34 months; P =.03), but they tended to be younger at diagnosis. The combined use of V(H)3-21/V(lambda)3-19 suggests a possible role for antigen(s) in the pathogenesis of these tumors and indicates that V(H)3-21(+) patients constitute a new MCL entity. 相似文献
133.
Management of patients with community-acquired pneumonia treated in hospital in Sweden 总被引:1,自引:0,他引:1
Hedlund J Ortqvist A Ahlqvist T Augustinsson A Beckman H Blanck C Burman LA Claesson B Qvarfordt I Elbel E Erntell M Follin P Goscinski G Holmberg H Höfer M Jorup C Lidman C Lindhusen E Rensfeldt G Rosenkvist E Stenlund G Stålberg A Verngren K Vig I Wendahl S;Swedish Infectious Diseases Society Pneumonia Study Group 《Scandinavian journal of infectious diseases》2002,34(12):887-892
To investigate the management of patients with community-acquired pneumonia (CAP) treated in hospital in Sweden, a multicentre retrospective cohort study was performed with medical record review of 982 patients (mean age 63 y) at 17 departments of infectious diseases at hospitals in Sweden. Information on antimicrobial therapy, demographic characteristics, comorbid conditions, physical examination findings, and laboratory and microbiological test results were recorded. Outcome measures were in-hospital mortality and length of hospital stay (LOS). Cultures were obtained from blood in 80% and from sputum in 22% of the patients. A microbiological aetiology was determined for 23% of the patients, with Streptococcus pneumoniae as the dominating agent (9%). The initial antibiotic treatment was mostly given intravenously (78%). Penicillin (50%) or a cephalosporin (30%) was the most common choice. Both of these drugs were usually given as a single agent. The overall mortality was 3.5% and the mean LOS was 6.4 d. Thus, the outcome was favourable despite the empirical antibiotic treatment having a narrow spectrum compared with the broader approach recommended in most recent guidelines on the management of CAP. These findings suggest that a majority of patients who are hospitalized with moderately severe pneumonia can be treated initially with penicillin alone. 相似文献
134.
Anna Ridderstad Wollberg Anders Ericsson-Dahlstrand Anders Juréus Petra Ekerot Sylvia Simon Maria Nilsson Stig-Johan Wiklund Anna-Lena Berg Mats Ferm Dan Sunnemark Rolf Johansson 《Proceedings of the National Academy of Sciences of the United States of America》2014,111(14):5409-5414
One hallmark of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE) is infiltration of leukocytes into the CNS, where chemokines and their receptors play a major mediatory role. CX3CR1 is a chemokine receptor involved in leukocyte adhesion and migration and hence a mediator of immune defense reactions. The role of CX3CR1 in MS and EAE pathogenesis however remains to be fully assessed. Here, we demonstrate CX3CR1 mRNA expression on inflammatory cells within active plaque areas in MS brain autopsies. To test whether blocking CNS infiltration of peripheral leukocytes expressing CX3CR1 would be a suitable treatment strategy for MS, we developed a selective, high-affinity inhibitor of CX3CR1 (AZD8797). The compound is active outside the CNS and AZD8797 treatment in Dark Agouti rats with myelin oligodendrocyte glycoprotein-induced EAE resulted in reduced paralysis, CNS pathology, and incidence of relapses. The compound is effective when starting treatment before onset, as well as after the acute phase. This treatment strategy is mechanistically similar to, but more restricted than, current very late antigen-4–directed approaches that have significant side effects. We suggest that blocking CX3CR1 on leukocytes outside the CNS could be an alternative approach to treat MS.Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and degenerative disease of the central nervous system (CNS). It was already discovered in the early 1900s that a similar disease could be induced in different animal species by injection of spinal cord extracts or myelin-derived proteins (1–3). This group of animal models for MS, called experimental autoimmune encephalomyelitis (EAE), has provided an experimental platform for building an extensive understanding of the pathology of MS, as well as discovering strategies for intervention of the disease. A typical feature of the pathogenesis in both MS and EAE is the infiltration of leukocytes from the blood stream into the CNS (3). Leukocyte adhesion and extravasation includes several well defined steps and various adhesion molecules, chemokines and their receptors are important mediators for this process. In line with this, the recently developed therapeutic drugs natalizumab and fingolimod, which broadly target leukocyte migration to the brain, exhibit efficacy in EAE models (4, 5), and they are now established therapies in MS (6).Natalizumab, blocking the interaction between very late antigen-4 (VLA-4) and CD106 (VCAM-1), is an effective treatment both on clinical endpoints and MRI biomarkers (7). Fingolimod, the first oral drug for relapsing remitting MS (RRMS), acts on S1P receptors preventing lymphocytes from moving out of lymphoid tissue (8). Natalizumab is only approved as a second-line monotherapy in RRMS or in patients with very active disease, because it carries increased risk of developing the often fatal progressive multifocal leukoencephalopathy (7, 9). Treatment with fingolimod is associated with side effects such as signs of immune suppression, including increased frequency of infections (8).Considering the pronounced presence of inflammatory cells in the brain of MS patients, the significant correlation between inflammation and axonal injury (10) and the efficiency of treatments that broadly block infiltration of immune cells, a similar but more restricted therapeutic approach is appealing. Chemokines are synthesized and released at sites of inflammation, where they act on specific receptors expressed by immune cells to mediate directed cell migration in synergy with adhesion molecules, such as VLA-4, from the blood stream and into the sites of inflammation. CX3CR1 is a unique member of the chemokine receptor family (11) and binds with high affinity to its ligand CX3CL1 [fractalkine (FKN)]. FKN is produced in a membrane bound form but can also be released following proteolytic cleavage, making it important for mediating both adhesion and migration of CX3CR1-expressing cells. In contrast to VLA-4, which is broadly expressed on most leukocytes except neutrophils (7, 12), the expression of CX3CR1 is restricted to subpopulations of monocytes, T lymphocytes, and natural killer (NK) cells (13–16). We have previously demonstrated intense accumulation of CX3CR1-expressing microglia/macrophages within inflammatory foci in the spinal cord of Dark Agouti (DA) rats with EAE induced by myelin oligodendrocyte glycoprotein (MOG) (17) and formed the hypothesis that CX3CR1 would be an attractive therapeutic target for treating MS.To test the hypothesis, we have developed a selective, high-affinity small-molecule inhibitor of CX3CR1 (AZD8797) (18). This molecule has the potential to be administered as an oral drug in humans. However, because of the decrease in potency to rat CX3CR1 and a modest oral bioavailability in rats (39%), we have chosen continuous s.c. dosing for the proof-of-concept studies in rats. The MOG1-125–induced EAE model in DA rats was used, because it exhibits pathology very similar to MS with infiltration of inflammatory cells, demyelination, and axonal degeneration in the CNS, as well as a relapsing remitting disease course (19, 20). To further mimic the human treatment situation, we have not only treated rats before the onset of paralysis but also initiated treatment during ongoing disease. We present efficacy (reduced paralysis) versus exposure data, analysis of CNS pathology, and measurements of functional inhibition of CX3CR1. These data, in combination with an analysis for CX3CR1 expression within MS brain autopsy samples, clearly demonstrate the potential of CX3CR1 inhibition as an alternative and unique approach for treating MS. 相似文献
135.
Gottipati Gopichand Berges Alienor C. Yang Shuying Chen Chao Karlsson Mats O. Plan Elodie L. 《Pharmaceutical research》2019,36(9):1-13
Pharmaceutical Research - Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel technique delivering drugs into the abdominal cavity as an aerosol under high pressure. It is... 相似文献
136.
Tove Wästerlid Sara Harrysson Therese M.-L. Andersson Sara Ekberg Gunilla Enblad Per-Ola Andersson Mats Jerkeman Sandra Eloranta Karin E. Smedby 《American journal of hematology》2020,95(7):740-748
Patients with diffuse large B-cell lymphoma (DLBCL) who fail to complete planned treatment with R-CHOP due to toxicity are sparsely described. We investigated the extent of failure to complete treatment (six cycles or more, or three cycles + RT for patients with stage I disease) with R-CHOP for reasons unrelated to non-response, the determinants of such failure and the outcome among these patients. Three thousand one hundred and forty nine adult DLBCL patients who started primary treatment with R-CHOP were identified through the Swedish lymphoma register 2007-2014. Of these, 147 (5%) stopped prematurely after 1-3 cycles of R-CHOP for reasons unrelated to non-response, 168 (5%) after 4-5 cycles and 2639 patients (84%) completed planned treatment. Additionally, 195 (6%) patients did not complete treatment due to non-response or death before treatment end. In a multivariable logistic regression model, age > 75 years, poor performance status, extranodal disease and Charlson Comorbidity Index ≥1 were significantly associated with failure to complete planned R-CHOP treatment for other reasons than non-response. Non-completion of treatment strongly correlated with survival. Five-year overall survival for patients who received 1-3 cycles was 26% (95% CI: 19%-33%), 49% (95% CI: 41%-57%) for 4-5 cycles and 76% (74%-77%) for patients who completed treatment. Failure to complete planned R-CHOP treatment is an important clinical issue associated with inferior survival. Old age and poor performance status most strongly predict such failure. These results indicate a need for improved treatment tailoring for patients with certain baseline demographics to improve tolerability and chance for treatment completion. 相似文献
137.
138.
Torbj?rn ?KERSTEDT Mats LEKANDER Helena PETERSéN G?ran KECKLUND John AXELSSON 《Industrial health》2014,52(1):36-42
Despite the common notion that stress impairs sleep there is little published data
showing that sleep (polysomnography (PSG)) is impaired across several sleep episodes in
individuals who complain of daily stress during the same period. The present paper aimed
at investigating such a connection. 33 subjects had 3 sleeps recorded with PSG at home
across 6 weeks and kept a sleep/wake diary each day, including 3-hourly ratings of stress
(scale 1–9). The stress ratings and the conventional PSG parameters were averaged across
time. A stepwise multiple regression analysis showed that the best predictors of stress
were Stage 1 sleep (beta = 0.49), latency to Stage 1 sleep (0.47) (adjusted for anxiety
and age). Other sleep continuity variables had significant correlations with stress
(reversed) but did not enter the multiple regression analysis. The correlation between
stress before the start of the study and PSG data was not significant. It was concluded
that moderately increased stress over a longer period of time is related to moderate signs
of disturbed sleep during that period. This may be of importance when considering stress
as a work environment problem. 相似文献
139.
Theresa Neimert-Andersson Jonas Binnmyr Mattias Enoksson Joakim Langebäck Louise Zettergren Anne-Charlotte Hällgren Henry Franzén Sara Lind Enoksson Pierre Lafolie Alf Lindberg Nabil Al-Tawil Mats Andersson Peter Singer Hans Grönlund Guro Gafvelin 《Vaccine》2014
ViscoGel, a chitosan-based hydrogel, has earlier been shown to improve humoral and cell-mediated immune responses in mice. In this study, a Phase I/IIa clinical trial was conducted to primarily evaluate safety and secondarily to study the effects of ViscoGel in combination with a model vaccine, Act-HIB to Haemophilus influenzae type b, administered as a single intramuscular injection. Healthy volunteers of both sexes, ages 22–50 and not previously vaccinated to HIB, were recruited. The trial had two phases. In Phase A, three ascending dose levels of ViscoGel (25, 50 and 75 mg) were evaluated for safety in 3 × 10 subjects. Phase B had a single-blind, randomised, parallel-group design evaluating safety and efficacy in five groups, 20 subjects/group, comparing vaccination with 0.2 μg or 2 μg Act-HIB alone or combined with ViscoGel (50 mg) and one group receiving the standard Act-HIB dose (10 μg). No safety or tolerability concerns were identified. Local, transient reactions at the injection site were the most common adverse events. These were more frequent in groups receiving Act-HIB + ViscoGel, while other AEs were recorded at similar frequency in Act-HIB and Act-HIB + ViscoGel groups. Efficacy was evaluated by measuring serum anti-HIB antibodies and cellular responses in peripheral blood mononuclear cells (PBMC). There was a large variation in baseline anti-HIB antibody titres and no adjuvant effect was observed on the anti-HIB antibody production in groups vaccinated with Act-HIB + ViscoGel. ELISpot analyses revealed increased interferon-γ (IFN-γ) responses to Act-HIB in PBMCs from subjects vaccinated with Act-HIB in combination with ViscoGel, compared to groups receiving Act-HIB alone. Moreover, ViscoGel counteracted an inhibitory effect of Act-HIB vaccination on the IFN-γ response to both the vaccine itself and an irrelevant influenza antigen. In summary, ViscoGel was found to be safe and well-tolerated, supporting further examination of ViscoGel as a new innovative vehicle for vaccine development. 相似文献
140.
Isobel M. Cameron Neil W. Scott Mats Adler Ian C. Reid 《Quality of life research》2014,23(10):2883-2888